Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease.

World J Crit Care Med

Department of Medicine, Rhode Island Hospital and Alpert Medical School, Bayliss, Division of Kidney and Hypertension, Brown University, Providence, RI 02906, United States.

Published: January 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Since the beginning of corona virus disease 2019 (COVID-19) pandemic, there has been a widespread use of remdesivir in adults and children. There is little known information about its outcomes in patients with end stage renal disease who are on dialysis.

Aim: To assess the clinical outcomes with use of remdesivir in adult patients with end stage kidney failure on hemodialysis.

Methods: A retrospective, multicenter study was conducted on patients with end stage renal disease on hemodialysis that were discharged after treatment for COVID-19 between April 1, 2020 and December 31, 2020. Primary endpoints were oxygen requirements, time to mortality and escalation of care needing mechanical ventilation.

Results: A total of 45 patients were included in the study. Twenty patients received remdesivir, and 25 patients did not receive remdesivir. Most patients were caucasian, females with diabetes mellitus and hypertension being the commonest comorbidities. There was a trend towards reduced oxygen requirement (beta = -25.93, (1) = 6.65, = 0.0099, probability of requiring mechanical ventilation (beta = -28.52, (1) = 22.98, 0.0001) and mortality (beta = -5.03, (1) = 7.41, = 0.0065) in patients that received remdesivir compared to the control group.

Conclusion: Larger studies are justified to study the effects of remdesivir in this high-risk population with end stage kidney disease on dialysis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788204PMC
http://dx.doi.org/10.5492/wjccm.v11.i1.48DOI Listing

Publication Analysis

Top Keywords

patients stage
16
stage renal
12
renal disease
12
patients
9
stage kidney
8
patients received
8
received remdesivir
8
remdesivir patients
8
remdesivir
6
stage
5

Similar Publications

The survival analysis of stage III and IV inoperable lung large cell neuroendocrine carcinoma and the role of LIPI in immunological stratification.

Lung Cancer

August 2025

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou, China; Guangzhou Institute of Respiratory Health, Guangzhou, C

Background: Large cell neuroendocrine carcinoma (LCNEC) represents a rare and unique type of lung tumor with an unfavorable prognosis. It is essential to summarize the treatment modalities and prognosis for inoperable stage III and IV LCNEC, explore the role of frontline immunotherapy, and examine the stratification role of the Lung Immune Prognostic Index (LIPI) and its relationship with the tumor microenvironment (TME).

Methods: This study retrospectively analyzed 160 patients with inoperable lung LCNEC (L-LCNEC) admitted to three hospitals from December 2012 to November 2023.

View Article and Find Full Text PDF

Introduction: Psychiatric comorbidities are increasingly recognized in patients with thoracic malignancies. We undertook this scoping review to characterize the management of thoracic malignancies in patients with psychiatric illness and uncover any disparities in operative treatment or perioperative outcomes.

Methods: We conducted a scoping review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

View Article and Find Full Text PDF

Background: Robotic single-port transvaginal natural orifice transluminal endoscopic surgery (RSP-vNOTES) is an emerging minimally invasive approach that combines the advantages of robotic surgery with scarless transvaginal access. Its application in gynecologic oncology remains limited, particularly for omentectomy during ovarian cancer staging.

Methods: We present the case of a 45-year-old woman with an ovarian granulosa cell tumor (GCT) who underwent supplemental staging surgery following unilateral oophorectomy.

View Article and Find Full Text PDF

Estimating Health State Utilities for IDH-Mutant Diffuse Glioma.

Pharmacoecon Open

September 2025

Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Rd, London, WC1X 8NL, UK.

Background: Isocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic treatment for years, but ultimately patients will experience recurrence and require radio- and/or chemotherapy (RT/CT). Cost-utility analyses (CUA) can explore the value of treatments that delay recurrence and initiation of RT/CT.

View Article and Find Full Text PDF

Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology.

Clin Transl Oncol

September 2025

Department of Basic Science, College of Medicine, Princess Nourah bint Abdulrahman, University, P.O.Box 84428, 11671, Riyadh, Saudi Arabia.

Esophageal cancer (EC) is one of the most serious health issues around the world, ranking seventh among the most lethal types of cancer and eleventh among the most common types of cancer worldwide. Traditional therapies-such as surgery, chemotherapy, and radiation therapy-often yield limited success, especially in the advanced stages of EC, prompting the pursuit of novel and more effective treatment strategies. Immunotherapy has emerged as a promising option; nonetheless, its clinical success is hindered by variable patient responses.

View Article and Find Full Text PDF